BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:MODERN TECHNOLOGIES FOR THE PRODUCTION OF NUCLEAR MEDICINE ISOTOPE
 S
DTSTART;VALUE=DATE-TIME:20220716T095000Z
DTEND;VALUE=DATE-TIME:20220716T102500Z
DTSTAMP;VALUE=DATE-TIME:20260608T121513Z
UID:indico-contribution-622@events.sinp.msu.ru
DESCRIPTION:Speakers: Vladimir Zherebchevsky (Saint-Petersburg State Unive
 rsity)\nIn modern nuclear medicine the main clinical information is obtain
 ed from observing the radiopharmaceuticals (by incorporating a radionuclid
 e into the pharmaceutical) distribution in the patient body. These pharmac
 euticals are a mixture of a biochemical agent and a radionuclide that emit
 s gamma quanta or positrons [1]. Diagnostic imaging with single-photon-emi
 tting radionuclides produces both planar images and single-photon emission
  computed tomography (SPECT) using a gamma camera. Radiopharmaceuticals la
 beled with positron-emitting radionuclides are used for positron emission 
 tomography (PET). Nuclear medicine images depict anatomic\, functional\, a
 nd metabolic processes in human body [2].\nAnother important task in nucle
 ar medicine methods is the targeted delivery of radiopharmaceuticals to ca
 ncer cells for the subsequent non-surgical treatment of the tumors. The co
 mbination of radionuclide imaging with radionuclide therapy in theranostic
 s (therapy + diagnostics) can give an excellent result for effective early
  diagnosis and treatment of various localized oncological tumors and oncol
 ogical diseases with minimal side effects [3]. Therefore\, one can produce
  the radiopharmaceuticals with the following properties: half-life should 
 be similar to the length of the medical procedure\, the radionuclide shoul
 d emit gamma rays (the energy of the gamma rays should be between 100 and 
 300 keV) together with emission of short-range charged particles (discrete
  spectrum for particles\, no recoil nuclei are produced when these particl
 es are emitted\, and they have a high linear energy of transfer)\, the rad
 ionuclide should be chemically suitable for incorporating into a pharmaceu
 tical without changing its biological behavior\, the pharmaceutical should
  localize only in the area of interest\, the radiopharmaceuticals should b
 e simple to prepare and have the low production price [1\,3].\nIn present 
 overview\, the technologies for the production of nuclear medicine isotope
 s (main components of novel radiopharmaceuticals) together with new nuclea
 r materials and specific nuclear reactions are discussed. Also the experim
 ental and theoretical studies of the (p\, xn) reactions excitation functio
 ns in the energy range 6-40 MeV for the light and medium mass nuclear syst
 ems with production of the scandium\, technetium and antimony radionuclide
 s were carried out. Such radionuclides should be prospective for the Thera
 nostics methods.\nAcknowledgments: this research has been conducted with f
 inancial support from St. Petersburg State University (project No 93025435
 ).\n\n1. P. F. Sharp\, H. G. Gemmell\, A. D. Murray\, Practical Nuclear Me
 dicine\, third edition\, \nSpringer–Verlag London Limited\, 2005.\n2. D.
  Volterrani\, P.A. Erba\, et.al.\, Nuclear Medicine: Methodology and Clini
 cal \napplications\, Vol.1\, Springer (2019).\n3. V. I. Zherebchevsky\, et
 .al.\,Bulletin of the Russian Academy of Sciences: Physics\, 2021\,   \nVo
 l. 85\, No. 10\, pp. 1128–1135.\n\nhttps://events.sinp.msu.ru/event/8/co
 ntributions/622/
LOCATION: Физический ф-т\, ЦФА
URL:https://events.sinp.msu.ru/event/8/contributions/622/
END:VEVENT
END:VCALENDAR